SEC Stock Data Quick Answer ZyVersa Therapeutics, Inc. reported Net Income of -$24.95 million for fiscal year 2025. ZyVersa Therapeutics, Inc. Net Income — Annual History Fiscal Year Net Income YoY Change 2025 -$24.95M -165.1% 2024 -$9.41M +90.4% 2023 -$98.30M -130932.5% 2022 -$75.0K +99.5% 2022 -$14.05M — Quarterly Net Income Quarter Ending Net Income YoY QoQ September 30, … Read more
Quick Answer ZyVersa Therapeutics, Inc. reported Net Income of -$24.95 million for fiscal year 2025. ZyVersa Therapeutics, Inc. — Key Financials by Year Metric 2025 2024 2023 2022 2021 Net Income -$24.95M-165.1% -$9.41M+90.4% -$98.30M-599.7% -$14.05M — Diluted EPS -$4.18+50.7% -$8.48+99.2% -$1089.70-109970.7% -$0.99 — Total Assets $347.9K-98.3% $20.60M-6.9% $22.11M-81.3% $118.51M+53.6% $77.14M Cash and Equivalents — — … Read more
Quick Answer ZEVRA THERAPEUTICS, INC. reported Shares Outstanding of 56.85 million shares for fiscal year 2025. ZEVRA THERAPEUTICS, INC. Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2025 56.85M +5.9% 2024 53.67M +29.2% 2023 41.53M +20.2% 2022 34.54M -1.3% 2021 35.01M +671.5% 2020 4.54M +99.7% 2019 2.27M +37.4% 2018 1.65M -88.7% 2017 … Read more
Quick Answer ZEVRA THERAPEUTICS, INC. reported Operating Income of -$62.94 million for fiscal year 2025. ZEVRA THERAPEUTICS, INC. Operating Income — Annual History Fiscal Year Operating Income YoY Change 2025 -$62.94M +27.7% 2024 -$87.00M -75.4% 2023 -$49.60M -16.5% 2022 -$42.56M -650.7% 2021 $7.73M +237.8% 2020 -$5.61M +72.4% 2019 -$20.34M +63.6% 2018 -$55.90M -67.5% 2017 -$33.37M … Read more
Quick Answer ZEVRA THERAPEUTICS, INC. reported R&D Expense of $10.16 million for fiscal year 2021. ZEVRA THERAPEUTICS, INC. R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2021 $10.16M +14.9% 2020 $8.84M -54.5% 2019 $19.41M -53.5% 2018 $41.76M +102.8% 2017 $20.59M +0.6% 2016 $20.47M +47.0% 2015 $13.93M +16.9% 2014 $11.92M +253.9% 2013 $3.37M … Read more
Quick Answer ZEVRA THERAPEUTICS, INC. reported Stockholders Equity of $154.66 million for fiscal year 2025. ZEVRA THERAPEUTICS, INC. Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 $154.66M +289.9% 2024 $39.67M -35.9% 2023 $61.86M +0.6% 2023 $61.52M -18.1% 2022 $75.12M -26.1% 2021 $101.66M +253.1% 2020 -$66.41M +10.8% 2019 -$74.46M -11.9% 2018 -$66.57M … Read more
Quick Answer ZEVRA THERAPEUTICS, INC. reported Long-Term Debt of $61.93 million for fiscal year 2025. ZEVRA THERAPEUTICS, INC. Long-Term Debt — Annual History Fiscal Year Long-Term Debt YoY Change 2025 $61.93M +4.1% 2024 $59.50M +1074.6% 2023 $5.07M — Quarterly Long-Term Debt Quarter Ending Long-Term Debt YoY QoQ September 30, 2025 $61.31M +4.1% +1.0% June 30, … Read more
Quick Answer ZEVRA THERAPEUTICS, INC. reported Cash and Equivalents of $62.41 million for fiscal year 2025. ZEVRA THERAPEUTICS, INC. Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2025 $62.41M +84.7% 2024 $33.78M -21.5% 2023 $43.05M -34.2% 2022 $65.47M -41.7% 2021 $112.35M +2566.7% 2020 $4.21M +31.0% 2019 $3.22M -82.5% 2018 $18.41M … Read more
Quick Answer ZEVRA THERAPEUTICS, INC. reported Total Assets of $284.73 million for fiscal year 2025. ZEVRA THERAPEUTICS, INC. Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $284.73M +59.8% 2024 $178.13M +3.4% 2023 $172.33M +49.4% 2022 $115.34M -13.2% 2021 $132.94M +1086.0% 2020 $11.21M +6.7% 2019 $10.51M -60.7% 2018 $26.75M -49.0% 2017 $52.46M … Read more
Quick Answer ZEVRA THERAPEUTICS, INC. reported Diluted EPS of $1.35 per share for fiscal year 2025. ZEVRA THERAPEUTICS, INC. Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2025 $1.35 +159.2% 2024 -$2.28 -8.1% 2021 -$2.11 +34.3% 2020 -$3.21 — Quarterly Diluted EPS Quarter Ending Diluted EPS YoY QoQ September 30, 2025 -$0.01 … Read more